Korea (DART K-IFRS) & Asia Semiconductor Primary-Filing Notes for Global Investors — Cross-Checked With U.S. SEC Disclosures
📊 Launch Interactive Valuation Scorecard & Full Filing Table on Asia Filing Notes →
Primary-Filing Valuation Verdict (UNDERVALUED (Suprema 7.1x P/E) vs OVERVALUED (Autoever 45x) · ▲ BULLISH Suprema·Satrec / ▼ CAUTIOUS HL Mando): Suprema (7.1x P/E, 17.3% OPM) & Satrec Offer Upside; HL Mando (Pre-Tax Loss) & Autoever (45x P/E) Face Pressure
Launch Interactive Valuation Scorecard & Full Filing Table on Asia Filing Notes →
| Issuer & Live Multiples | Valuation & 6–12M Direction | Primary-Filing Basis & Catalyst |
|---|---|---|
| Suprema (236200.KQ) Mkt Cap 362B KRW · P/E 7.07x · P/B 1.20x · Core OPM 17.3% | UNDERVALUED (▲ Bullish) | Core 17.3% OPM at 7.1x P/E is undervalued once non-operating FX/financial noise clears |
| Satrec Initiative (099320.KQ) Mkt Cap 632B KRW · Cap/Ann.3Q OP 19.2x · P/B 2.56x | UNDERVALUED (▲ Bullish) | 3Q OPM breakout to 14.7% compresses annualized operating multiple to 19.2x |
| SOOP (067160.KQ) Mkt Cap 373B KRW · P/E 4.36x · Fwd P/E 5.36x · P/B 0.77x | FAIR (▶ Neutral) | 4.4x P/E prices in YoY contraction; awaits top-line re-acceleration trigger |
| Hyundai Autoever (307950.KS) Mkt Cap 8.57T KRW · P/E 44.92x · Fwd P/E 40.44x · P/B 4.53x | OVERVALUED (▼ Cautious) | Fwd P/E 40.4x is stretched against 5.63% OPM and -23.9% QoQ OP contraction |
| HL Mando (204320.KS) Mkt Cap 1.64T KRW · P/E 9.68x · P/B 0.56x (3Q Net Loss) | OVERVALUED (▼ Cautious) | 2.22% OPM plus -92.7B KRW non-op loss creates a near-term earnings value trap |
Reading all 4 lines of the Korean DART preliminary table exposes a -92.74B KRW non-operating swing at KOSPI's HL Mando and a -23.52B KRW swing at KOSDAQ's Suprema—alongside a +502.7% QoQ OP breakout at Satrec Initiative.
As of 2026.10.31 · Source: Korean FSS DART K-IFRS Preliminary 3Q26 Earnings & Material Management Filings (2026.10.29–10.30) · Derived ratios marked (Calc.).
Left: 3Q26 Operating Profit vs. Pre-Tax Continuing Income at KOSPI's Hyundai AutoEver (307950.KS) and HL Mando (204320.KS, showing a -92.74B KRW non-operating swing). Right: 3Q26 Operating Profit vs. Pre-Tax Continuing Income across KOSDAQ's SOOP (067160.KQ), Suprema (236200.KQ, -23.52B KRW non-operating swing), and Satrec Initiative (099320.KQ) [2][3][4][5][6].
연결재무제표기준 영업(잠정)실적 공정공시) print Revenue, OP, Pre-Tax Continuing Income, and Net Income [1][2][3][4][5][6][7]. Stopping at line 2 (OP) misses below-the-line FX/financial/impairment shocks.| Issuer (Market & Ticker) | 3Q26 Operating Profit vs. Pre-Tax Continuing Income (DART) |
|---|---|
| Kia Corporation (KOSPI: 000270.KS) |
Rev 31.60T KRW (-4.4% QoQ, +10.1% YoY); OP 1.82T KRW (-30.8% QoQ, +24.3% YoY; 5.75% OPM Calc. vs. 7.96% in 2Q26); Pre-tax 1.82T KRW (-40.6% QoQ, -3.4% YoY); Net profit 1.29T KRW (-44.8% QoQ, -9.6% YoY) [1] |
| Hyundai AutoEver (KOSPI: 307950.KS) |
Rev 1,224.70B KRW (-2.1% QoQ, +16.2% YoY); OP 68.91B KRW (-23.9% QoQ, -2.6% YoY; 5.63% OPM Calc.); Pre-tax 60.18B KRW (-34.3% QoQ, -14.7% YoY); Net profit 44.93B KRW (-35.4% QoQ, -14.9% YoY) [2] |
| HL Mando (KOSPI: 204320.KS) |
Rev 2,320.53B KRW (-7.0% QoQ, 0.0% YoY); OP +51.54B KRW (-51.8% QoQ, -45.3% YoY; 2.22% OPM Calc.), but Pre-Tax Continuing Income swung to -41.20B KRW loss (-92.74B KRW non-op gap, Calc.); Net loss -42.51B KRW [3] |
| Suprema (KOSDAQ: 236200.KQ) |
Rev 32.84B KRW (-18.59% QoQ, +8.20% YoY); OP +5.67B KRW (17.26% OPM Calc.; 9M26 OPM 20.34% Calc.), but Pre-Tax Continuing Income swung to -17.85B KRW loss (-23.52B KRW non-op gap, Calc.); Net loss -12.64B KRW [4] |
| SOOP (KOSDAQ: 067160.KQ) |
Rev 105.69B KRW (+1.8% QoQ, -16.0% YoY); OP 14.52B KRW (+15.0% QoQ, -59.9% YoY; 13.74% OPM Calc. vs. 28.81% in 3Q25); Pre-tax 13.19B KRW (-19.3% QoQ, -65.1% YoY); Net profit 10.58B KRW (+21.0% QoQ, -64.0% YoY) [5] |
| Satrec Initiative (KOSDAQ: 099320.KQ) |
Rev 56.19B KRW (+9.9% QoQ, +11.4% YoY); OP 8.24B KRW (+502.7% QoQ vs. 1.37B KRW, +235.6% YoY; 14.66% OPM Calc. vs. 2.67% in 2Q26); Pre-tax 3.67B KRW (+698.5% QoQ); Net profit turned positive at 3.39B KRW [6] |
| AbClon (KOSDAQ: 174900.KQ) |
Final settlement & full IP assignment agreement with Yuhan Corporation on 2016 TIGIT antibody joint R&D contract; settlement receipt 1.00B KRW (≥10% of prior-year rev); zero remaining obligations or contingent liabilities [7] |
추가적인 이행 의무나 우발부채는 존재하지 않습니다) [7].OPM with Pre-Tax minus OP on Korean preliminary releases to separate true operating inflections (Satrec +502.7% QoQ OP) from non-operating shocks (HL Mando -92.74B KRW; Suprema -23.52B KRW).Read the complete interactive edition—including live valuation gauges, downloadable K-IFRS / SEC Form 10-Q reconciliation tables, and direct DART receipt (rcpNo) & EDGAR links—on our primary research portal:
Personal analysis record based on public regulatory filings. Not investment advice or a solicitation to buy or sell any security.